Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allon Therapeutics, Inc.
Study confirms blood brain barrier penetration of AL-108 and AL-208
July 6th, 2005
Allon Therapeutics, Inc., (NPC) announced that new preclinical animal studies have confirmed that its lead product candidates AL-108 and AL-208 penetrate the blood brain barrier and reach their target therapeutic areas in the central nervous system. The blood-brain barrier is the system of capillary endothelial cells that protects the brain from harmful substances in the blood stream - and also prevents the permeation of many therapeutic drugs into the brain. Research has established that most neuropeptides, molecules comprised of combinations of amino acids that are released by brain cells as intracellular messengers and growth factors, are normally...
Source: Biotech Week (2005-07-06)
|
